Literature DB >> 20448201

Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome.

Jerome Dickstein1, Vitalyi Senyuk, Kavitha Premanand, Leopoldo Laricchia-Robbio, Peng Xu, Francesca Cattaneo, Raffaella Fazzina, Giuseppina Nucifora.   

Abstract

By expressing EVI1 in murine bone marrow (BM), we previously described a myelodysplastic syndrome (MDS) model characterized by pancytopenia, dysmegakaryopoiesis, dyserythropoiesis, and BM failure. The mice invariably died 11-14 months after BM transplantation (BMT). Here, we show that a double point mutant EVI1-(1+6Mut), unable to bind Gata1, abrogates the onset of MDS in the mouse and re-establishes normal megakaryopoiesis, erythropoiesis, BM function, and peripheral blood profiles. These normal features were maintained in the reconstituted mice until the study was ended at 21 months after BMT. We also report that EVI1 deregulates several genes that control cell division and cell self-renewal. In striking contrast, these genes are normalized in the presence of the EVI1 mutant. Moreover, EVI1, but not the EVI1 mutant, seemingly deregulates these cellular processes by altering miRNA expression. In particular, the silencing of miRNA-124 by DNA methylation is associated with EVI1 expression, but not that of the EVI1 mutant, and appears to play a key role in the up-regulation of cell division in murine BM cells and in the hematopoietic cell line 32Dcl3. The results presented here demonstrate that EVI1 induces MDS in the mouse through two major pathways, both of which require the interaction of EVI1 with other factors: one, results from EVI1-Gata1 interaction, which deregulates erythropoiesis and leads to fatal anemia, whereas the other occurs by interaction of EVI1 with unidentified factors causing perturbation of the cell cycle and self-renewal, as a consequence of silencing miRNA-124 by EVI1 and, ultimately, ensues in BM failure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20448201      PMCID: PMC2906858          DOI: 10.1073/pnas.1004297107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

Review 1.  Myelodysplasia.

Authors:  M L Heaney; D W Golde
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

2.  Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells.

Authors:  Boris Calmels; Cole Ferguson; Mikko O Laukkanen; Rima Adler; Marion Faulhaber; Hyeoung-Joon Kim; Stephanie Sellers; Peiman Hematti; Manfred Schmidt; Christof von Kalle; Keiko Akagi; Robert E Donahue; Cynthia E Dunbar
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

3.  Bmi1 is expressed in vivo in intestinal stem cells.

Authors:  Eugenio Sangiorgi; Mario R Capecchi
Journal:  Nat Genet       Date:  2008-06-08       Impact factor: 38.330

Review 4.  Hox genes: from leukemia to hematopoietic stem cell expansion.

Authors:  Carolina Abramovich; Nicolas Pineault; Hideaki Ohta; R Keith Humphries
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

5.  Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells.

Authors:  Leopoldo Laricchia-Robbio; Raffaella Fazzina; Donglan Li; Ciro R Rinaldi; Kisaly K Sinha; Soumen Chakraborty; Giuseppina Nucifora
Journal:  Mol Cell Biol       Date:  2006-09-05       Impact factor: 4.272

6.  Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts.

Authors:  A Kilbey; V Stephens; C Bartholomew
Journal:  Cell Growth Differ       Date:  1999-09

7.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

8.  Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1.

Authors:  Leopoldo Laricchia-Robbio; Giuseppina Nucifora
Journal:  Blood Cells Mol Dis       Date:  2007-10-29       Impact factor: 3.039

Review 9.  Myelodysplastic syndromes.

Authors:  Stephen D Nimer
Journal:  Blood       Date:  2008-05-15       Impact factor: 22.113

10.  Bmi1 and cell of origin determinants of brain tumor phenotype.

Authors:  Peter Dirks
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

View more
  28 in total

1.  The Evi1, microRNA-143, K-Ras axis in colon cancer.

Authors:  Jin-Song Gao; Yingjie Zhang; Xiaoli Tang; Lynne D Tucker; Patrick M Tarwater; Peter J Quesenberry; Isidore Rigoutsos; Bharat Ramratnam
Journal:  FEBS Lett       Date:  2011-01-26       Impact factor: 4.124

2.  Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.

Authors:  Iria Vázquez; Miren Maicas; Nerea Marcotegui; Ana Conchillo; Elisabet Guruceaga; José Roman-Gomez; María J Calasanz; Xabier Agirre; Felipe Prosper; María D Odero
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-07       Impact factor: 11.205

3.  Methylation and microRNA-mediated epigenetic regulation of SOCS3.

Authors:  Chandra S Boosani; Devendra K Agrawal
Journal:  Mol Biol Rep       Date:  2015-04       Impact factor: 2.316

Review 4.  MicroRNAs as regulatory elements in immune system logic.

Authors:  Arnav Mehta; David Baltimore
Journal:  Nat Rev Immunol       Date:  2016-04-28       Impact factor: 53.106

5.  Epigenetic regulation of miRNA-124 and multiple downstream targets is associated with treatment response in myeloid malignancies.

Authors:  Hongbin Liu; Phillip Pattie; Sahan Chandrasekara; Andrew Spencer; Anthony E Dear
Journal:  Oncol Lett       Date:  2016-07-25       Impact factor: 2.967

Review 6.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

7.  EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2.

Authors:  M Gómez-Benito; A Conchillo; M A García; I Vázquez; M Maicas; C Vicente; I Cristobal; N Marcotegui; L García-Ortí; E Bandrés; M J Calasanz; M M Alonso; M D Odero
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

Review 8.  Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.

Authors:  Diamantina Vasilatou; Sotirios G Papageorgiou; George Dimitriadis; Vasiliki Pappa
Journal:  Epigenetics       Date:  2013-05-09       Impact factor: 4.528

9.  Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis.

Authors:  Vitalyi Senyuk; Yunyuan Zhang; Yang Liu; Ming Ming; Kavitha Premanand; Lan Zhou; Ping Chen; Jianjun Chen; Janet D Rowley; Giuseppina Nucifora; Zhijian Qian
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

10.  EVI1 splice variants modulate functional responses in ovarian cancer cells.

Authors:  Punashi Dutta; Tuyen Bui; Kyle A Bauckman; Khandan Keyomarsi; Gordon B Mills; Meera Nanjundan
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.